

### **REMARKS**

The claims have been amended to place them in a format more customary to US patent practice. Claim 11 has been amended to include the features of hydroxypyridonone of formula (I-III). Support for the amendment to claim 11 can be found, for example, in original claim 1. Support for new claims 15-19, can be found on page 4 of the specification. No new matter has been added.

### **Restriction and Election**

Applicants hereby elect with traverse, claims 11-14 (Group II) drawn to a method for the treatment of SMD. Applicants further elect hydroxypyridonone of formula (I).


The requirement is respectfully traversed because the Examiner has not established that searching all the claims would constitute an undue burden.

Unity of invention for the subject matter of the claims does exist.

Thus, it is respectfully requested that the restriction requirement be withdrawn.

Applicants do not believe that any fees are due for this submission, but the Examiner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402 should the Examiner determine otherwise.

Respectfully submitted,

  
\_\_\_\_\_  
Anthony Zelano Reg. 27,969  
Attorney for Applicant(s)

\_\_\_\_\_  
Jennifer Branigan Reg. 40,921  
Agent for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410  
Attorney Docket No.: MARGI-0044  
Date: 9 November 2007

JJB:K:\margi\44\Response to Restriction.doc